Partial TrkB receptor activation suppresses cortical epileptogenesis through actions on parvalbumin interneurons
Post-traumatic epilepsy is one of the most common and difficult to treat forms of acquired epilepsy worldwide. Currently, there is no effective way to prevent post-traumatic epileptogenesis. It is known that abnormalities of interneurons, particularly parvalbumin-containing interneurons, play a crit...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2018-05-01
|
| Series: | Neurobiology of Disease |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S096999611830024X |
| _version_ | 1818574413419773952 |
|---|---|
| author | Feng Gu Isabel Parada Tao Yang Frank M. Longo David A. Prince |
| author_facet | Feng Gu Isabel Parada Tao Yang Frank M. Longo David A. Prince |
| author_sort | Feng Gu |
| collection | DOAJ |
| description | Post-traumatic epilepsy is one of the most common and difficult to treat forms of acquired epilepsy worldwide. Currently, there is no effective way to prevent post-traumatic epileptogenesis. It is known that abnormalities of interneurons, particularly parvalbumin-containing interneurons, play a critical role in epileptogenesis following traumatic brain injury. Thus, enhancing the function of existing parvalbumin interneurons might provide a logical therapeutic approach to prevention of post-traumatic epilepsy. The known positive effects of brain-derived neurotrophic factor on interneuronal growth and function through activation of its receptor tropomyosin receptor kinase B, and its decrease after traumatic brain injury, led us to hypothesize that enhancing trophic support might improve parvalbumin interneuronal function and decrease epileptogenesis. To test this hypothesis, we used the partial neocortical isolation (‘undercut’, UC) model of posttraumatic epileptogenesis in mature rats that were treated for 2 weeks, beginning on the day of injury, with LM22A-4, a newly designed partial agonist at the tropomyosin receptor kinase B. Effects of treatment were assessed with Western blots to measure pAKT/AKT; immunocytochemistry and whole cell patch clamp recordings to examine functional and structural properties of GABAergic interneurons; field potential recordings of epileptiform discharges in vitro; and video-EEG recordings of PTZ-induced seizures in vivo. Results showed that LM22A-4 treatment 1) increased pyramidal cell perisomatic immunoreactivity for VGAT, GAD65 and parvalbumin; 2) increased the density of close appositions of VGAT/gephyrin immunoreactive puncta (putative inhibitory synapses) on pyramidal cell somata; 3) increased the frequency of mIPSCs in pyramidal cells; and 4) decreased the incidence of spontaneous and evoked epileptiform discharges in vitro. 5) Treatment of rats with PTX BD4–3, another partial TrkB receptor agonist, reduced the incidence of bicuculline-induced ictal episodes in vitro and PTZ induced electrographic and behavioral ictal episodes in vivo. 6) Inactivation of TrkB receptors in undercut TrkBF616A mice with 1NMPP1 abolished both LM22A-4-induced effects on mIPSCs and on increased perisomatic VGAT-IR. Results indicate that chronic activation of the tropomyosin receptor kinase B by a partial agonist after cortical injury can enhance structural and functional measures of GABAergic inhibition and suppress posttraumatic epileptogenesis. Although the full agonist effects of brain-derived neurotrophic factor and tropomyosin receptor kinase B activation in epilepsy models have been controversial, the present results indicate that such trophic activation by a partial agonist may potentially serve as an effective therapeutic option for prophylactic treatment of posttraumatic epileptogenesis, and treatment of other neurological and psychiatric disorders whose pathogenesis involves impaired parvalbumin interneuronal function. |
| first_indexed | 2024-12-15T00:26:19Z |
| format | Article |
| id | doaj.art-f3e101a2c58f4b6ba535edc84e4ab141 |
| institution | Directory Open Access Journal |
| issn | 1095-953X |
| language | English |
| last_indexed | 2024-12-15T00:26:19Z |
| publishDate | 2018-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Neurobiology of Disease |
| spelling | doaj.art-f3e101a2c58f4b6ba535edc84e4ab1412022-12-21T22:42:10ZengElsevierNeurobiology of Disease1095-953X2018-05-011134558Partial TrkB receptor activation suppresses cortical epileptogenesis through actions on parvalbumin interneuronsFeng Gu0Isabel Parada1Tao Yang2Frank M. Longo3David A. Prince4Department of Neurology and Neurological Sciences, Stanford University School of Medicine, United StatesDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, United StatesDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, United StatesDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, United StatesCorresponding author at: Stanford Medical Center, 300 Pasteur Dr., Room M016, Stanford, CA, 94028, United States.; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, United StatesPost-traumatic epilepsy is one of the most common and difficult to treat forms of acquired epilepsy worldwide. Currently, there is no effective way to prevent post-traumatic epileptogenesis. It is known that abnormalities of interneurons, particularly parvalbumin-containing interneurons, play a critical role in epileptogenesis following traumatic brain injury. Thus, enhancing the function of existing parvalbumin interneurons might provide a logical therapeutic approach to prevention of post-traumatic epilepsy. The known positive effects of brain-derived neurotrophic factor on interneuronal growth and function through activation of its receptor tropomyosin receptor kinase B, and its decrease after traumatic brain injury, led us to hypothesize that enhancing trophic support might improve parvalbumin interneuronal function and decrease epileptogenesis. To test this hypothesis, we used the partial neocortical isolation (‘undercut’, UC) model of posttraumatic epileptogenesis in mature rats that were treated for 2 weeks, beginning on the day of injury, with LM22A-4, a newly designed partial agonist at the tropomyosin receptor kinase B. Effects of treatment were assessed with Western blots to measure pAKT/AKT; immunocytochemistry and whole cell patch clamp recordings to examine functional and structural properties of GABAergic interneurons; field potential recordings of epileptiform discharges in vitro; and video-EEG recordings of PTZ-induced seizures in vivo. Results showed that LM22A-4 treatment 1) increased pyramidal cell perisomatic immunoreactivity for VGAT, GAD65 and parvalbumin; 2) increased the density of close appositions of VGAT/gephyrin immunoreactive puncta (putative inhibitory synapses) on pyramidal cell somata; 3) increased the frequency of mIPSCs in pyramidal cells; and 4) decreased the incidence of spontaneous and evoked epileptiform discharges in vitro. 5) Treatment of rats with PTX BD4–3, another partial TrkB receptor agonist, reduced the incidence of bicuculline-induced ictal episodes in vitro and PTZ induced electrographic and behavioral ictal episodes in vivo. 6) Inactivation of TrkB receptors in undercut TrkBF616A mice with 1NMPP1 abolished both LM22A-4-induced effects on mIPSCs and on increased perisomatic VGAT-IR. Results indicate that chronic activation of the tropomyosin receptor kinase B by a partial agonist after cortical injury can enhance structural and functional measures of GABAergic inhibition and suppress posttraumatic epileptogenesis. Although the full agonist effects of brain-derived neurotrophic factor and tropomyosin receptor kinase B activation in epilepsy models have been controversial, the present results indicate that such trophic activation by a partial agonist may potentially serve as an effective therapeutic option for prophylactic treatment of posttraumatic epileptogenesis, and treatment of other neurological and psychiatric disorders whose pathogenesis involves impaired parvalbumin interneuronal function.http://www.sciencedirect.com/science/article/pii/S096999611830024XEpilepsyBDNFNeocortical injuryTrophicAnti-epileptogenesis |
| spellingShingle | Feng Gu Isabel Parada Tao Yang Frank M. Longo David A. Prince Partial TrkB receptor activation suppresses cortical epileptogenesis through actions on parvalbumin interneurons Neurobiology of Disease Epilepsy BDNF Neocortical injury Trophic Anti-epileptogenesis |
| title | Partial TrkB receptor activation suppresses cortical epileptogenesis through actions on parvalbumin interneurons |
| title_full | Partial TrkB receptor activation suppresses cortical epileptogenesis through actions on parvalbumin interneurons |
| title_fullStr | Partial TrkB receptor activation suppresses cortical epileptogenesis through actions on parvalbumin interneurons |
| title_full_unstemmed | Partial TrkB receptor activation suppresses cortical epileptogenesis through actions on parvalbumin interneurons |
| title_short | Partial TrkB receptor activation suppresses cortical epileptogenesis through actions on parvalbumin interneurons |
| title_sort | partial trkb receptor activation suppresses cortical epileptogenesis through actions on parvalbumin interneurons |
| topic | Epilepsy BDNF Neocortical injury Trophic Anti-epileptogenesis |
| url | http://www.sciencedirect.com/science/article/pii/S096999611830024X |
| work_keys_str_mv | AT fenggu partialtrkbreceptoractivationsuppressescorticalepileptogenesisthroughactionsonparvalbumininterneurons AT isabelparada partialtrkbreceptoractivationsuppressescorticalepileptogenesisthroughactionsonparvalbumininterneurons AT taoyang partialtrkbreceptoractivationsuppressescorticalepileptogenesisthroughactionsonparvalbumininterneurons AT frankmlongo partialtrkbreceptoractivationsuppressescorticalepileptogenesisthroughactionsonparvalbumininterneurons AT davidaprince partialtrkbreceptoractivationsuppressescorticalepileptogenesisthroughactionsonparvalbumininterneurons |